1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

28 Feb 2024
Admin
News Article

One Up, One Down: Allecra Scores FDA Nod for Antibiotic Combo After Venatorx Hit with Rejection

One Up, One Down: Allecra scores FDA nod for antibiotic combo after Venatorx hit with rejection

Over the last few days, as the FDA rejected one antibiotic combination treatment for complicated urinary tract infections (cUTIs), it has approved another.

The United States regulator has signed off on Allecra Therapeutics’ Exblifep (cefepime/enmatazobactam) as a treatment for cUTIs, including the severe kidney condition pyelonephritis, brought on by gram-negative bacteria.

Previous Rejection

Meanwhile, the FDA handed out a rejection last week in the same indication for Venatorx Pharmaceuticals and Melinta Therapeutics’ antibiotic combo treatment cefepime/taniborbactam.

Additional Market Exclusivity

As part of the approval, the FDA has extended Allecra five years of additional market exclusivity as part of the Generating Antibiotic Incentives Now (GAIN) Act.
That exclusivity now will run through 2032, the company said. GAIN incentivizes the creation of new anti-infective therapeutics by providing benefits to manufacturers of qualified infectious disease products (QIDPs).

Orchid Pharma and other Antibiotics

Orchid Pharma, which discovered enmatazobactam, established Allecra in 2013 to take on development of the extended-spectrum beta-lactamase inhibitor (BLI) outside of India.
Cefepime, which was developed by Bristol Myers Squibb and approved in 1994, is a beta-lactam antibiotic. Because of its increasing ineffectiveness, cefepime was removed from the World Health Organization’s list of essential medicines in 2019.

Words form Allecra

“Receiving FDA approval is a tremendous achievement for Allecra and a testament to the hard work and dedication of a small, yet highly focused team of individuals,” Iain Buchanan, Allecra’s supervisory board member, said in a release. The approval was backed by a phase 3 trial which showed the superiority of cefepime/enmatazobactam to the standard of care, piperacillin/tazobactam, in clinical cure rates and microbiological eradication.

CHMP’s Approval for Hospital Use

In January, Europe’s Committee of Medicinal Products for Human Use (CHMP) provided a positive opinion on cefepime/enmatazobactam. Additionally, the European Medicines Agency (EMA) said that the combo is eligible for approval for use in hospital-acquired ventilator-associated bacterial pneumonia.

Allecra Partnersip

Allecra has signed license agreements for Exblifep with Advanz Pharma in Europe and with Shanghai Haini Pharmaceutical in China.
The company is in “discussions with strategic partners” for launching Exblifep in the U.S., Buchanan said in a statement.
As for the complete response letter (CRL) the FDA sent to Venatorx and Melinta, the regulator did not flag any clinical safety or efficacy problems but did identify a manufacturing issue.

The Sponsors

The companies' efforts with the combo are being funded by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Department of Health and Human Services and the Biomedical Advanced Research and Development Authority.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!